Upadacitinib: First Approval

online resource

posted on 2019-11-26, 20:59 authored by Sean Duggan, Susan J. Keam

Compliance with Ethical Standards

Funding: The preparation of this review was not supported by any external funding.

Conflicts of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sean Duggan and Susan Keam are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

Additional information about this Adis Drug Review can be found here

Abstract

Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.

History

Usage metrics

Keywords

Upadacitinib Adis Drug Review Adis Insight Report First Approval Janus kinase 1 inhibitor Rheumatoid arthritis

Licence

CC BY-NC 4.0

Upadacitinib: First Approval

History

Usage metrics

Categories

Keywords

Licence

Exports